Literature DB >> 2329412

Membranoproliferative glomerulonephritis: the Cincinnati experience--cumulative renal survival from 1957 to 1989.

P T McEnery1.   

Abstract

Seventy-six children with idiopathic MPGN have been followed at this medical center since 1957 (mean 10.6 years of disease). Seventy-one of the children have been treated with a regimen of prednisone (mean 7.7 years of treatment). Monotherapy with alternate-day prednisone was used in 50 of the children. Other immunosuppressive and cytotoxic drugs have not been used since 1981. In the 71 treated patients, the cumulative renal survival (creatinine less than 3.0 mg/dl (265.5 mumol/L)) was 82% in the tenth year and 56% in the twentieth year after disease onset. Cumulative renal survival, calculated from the date of initiation of the prednisone regimen, was 75% in the tenth year and 59% in the twentieth year. As our experience with this disease has increased, long-term cumulative renal survival has improved.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329412     DOI: 10.1016/s0022-3476(05)82712-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

1.  Remission of membranoproliferative nephritis with angiotensin converting enzyme inhibition and receptor blockade.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

2.  Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J Bernstein; J N Tobin; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

3.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).

Authors:  M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

4.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

5.  Long-term follow-up of atypical membranoproliferative glomerulonephritis: are steroids indicated?

Authors:  Teruo Fujita; Kandai Nozu; Kazumoto Iijima; Ichiro Kamioka; Kunihiko Yoshiya; Ryojiro Tanaka; Kiyoshi Hamahira; Koichi Nakanishi; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

6.  Long-term follow-up of diffuse membranoproliferative glomerulonephritis type I.

Authors:  Takeshi Yanagihara; Mari Hayakawa; Junko Yoshida; Masami Tsuchiya; Toshisada Morita; Mutsumi Murakami; Yoshitaka Fukunaga
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

7.  Prognostic factors in children with membranoproliferative glomerulonephritis type I.

Authors:  Silvestre García-de la Puente; Iraida Luz Orozco-Loza; Samuel Zaltzman-Girshevich; Beatriz de Leon Bojorge
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

Review 8.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

9.  Transition of children with membranoproliferative glomerulonephritis to adolescence and adulthood.

Authors:  Kikuo Iitaka; Osamu Motoyama; Shinya Nakamura; Hiroe Koshino; Tadasu Sakai
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

10.  C3 nephritic factor associated with C3 glomerulopathy in children.

Authors:  Camille Nicolas; Vincent Vuiblet; Veronique Baudouin; Marie-Alice Macher; Isabele Vrillon; Nathalie Biebuyck-Gouge; Maud Dehennault; Sophie Gié; Denis Morin; Hubert Nivet; François Nobili; Tim Ulinski; Bruno Ranchin; Maria Chiarra Marinozzi; Stéphanie Ngo; Véronique Frémeaux-Bacchi; Christine Pietrement
Journal:  Pediatr Nephrol       Date:  2013-09-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.